Consensus Immuneering Corporation

Stocks

IMRX

US45254E1073

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:31:48 2026-08-27 EDT			5-day change	1st Jan Change
5.195 ^USD	+0.87%		-1.62%	-21.50%

08-26	Immuneering Reports FDA Approval Of New Second-Line Metastatic Pancreatic Cancer Treatment And Provides Update On Atebimetinib Phase 3 MAPKeeper 301 Trial	CI
08-06	HC Wainwright Initiates Immuneering at Buy With $14 Price Target	MT

Evolution of the Average Target: Immuneering Corporation

Evolution of the Target Price: Immuneering Corporation

Changes in Analyst Recommendations: Immuneering Corporation

e50310a1467ef1ee98d8f5.VeKxtPCepH2zW5hBzX5jQd2QPNddwtjj3zUJwBGhQgY.IdL9-ZnMlC_bPvoVqAcJDZzCXYEIl-2PpgF-iGnONGcckf-Dv_vjEOcd-w~ea8e094a8df5039b08ef16fed163f0d0

Analysts' recommendations: Immuneering Corporation

08-06	HC Wainwright Initiates Immuneering at Buy With $14 Price Target	MT
25-10-31	Leerink Partners Initiates Immuneering at Outperform With $15 Price Target	MT
25-09-26	Chardan Raises Price Target on Immuneering to $20 From $13, Keeps Buy Rating	MT
25-06-18	Mizuho Raises Price Target on Immuneering to $10 From $8, Keeps Outperform Rating	MT
24-12-13	Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5	MT
24-09-13	Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating	MT
24-08-07	Chardan Adjusts Immuneering Price Target to $16 From $12, Maintains Buy Rating	MT
24-04-02	Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating	MT
24-03-15	Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16	MT
24-03-15	Needham Adjusts Price Target on Immuneering to $15 From $20, Maintains Buy Rating	MT
24-03-15	Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating	MT
24-03-15	Guggenheim Downgrades Immuneering to Neutral From Buy	MT
24-03-15	TD Cowen Downgrades Immuneering to Market Perform From Outperform	MT
23-12-01	Needham Starts Coverage on Immuneering with Buy Rating, $20 Price Target	MT
23-04-19	Morgan Stanley Upgrades Immuneering to Equalweight From Underweight, Adjusts Price Target to $14 From $5	MT
23-04-19	Mizuho Upgrades Immuneering to Buy From Neutral, Adjusts Price Target to $20 From $10	MT
23-04-19	Chardan Raises Price Target on Immuneering to $22 From $18, Maintains Buy Rating	MT
23-03-30	Mizuho Initiates Immuneering at Neutral With $10 Price Target	MT
23-02-03	Morgan Stanley Downgrades Immuneering to Underweight From Equal Weight, Adjusts Price Target to $5 From $12	MT
22-07-14	Morgan Stanley Adjusts Price Target for Immuneering to $12 From $18, Maintains Equalweight Rating	MT
22-07-08	Chardan Capital Initiates Immuneering at Buy with $18 PT on Pipeline Potential, Translational Bioinformatic Platform	MT
22-07-08	Chardan Capital Initiates Immuneering at Buy with $18 Price Target	MT
22-04-01	Oppenheimer Initiates Coverage on Immuneering With Outperform Rating, $26 Price Target	MT
22-01-07	Piper Sandler Starts Immuneering at Overweight With $41 Price Target	MT
22-01-03	Guggenheim Adjusts Price Target for Immuneering to $30 From $42, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
IMMUNEERING CORPORATION		+241.19%
WUXI APPTEC CO., LTD.		+14.62%
ARGENX SE	-	+7.51%
BIONTECH SE		+7.74%
WUXI BIOLOGICS (CAYMAN) INC.		+6.28%
INSMED INCORPORATED		+60.93%
GENMAB A/S		+11.65%
PHARMAESSENTIA CORPORATION		-15.34%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+18.07%
EXELIXIS, INC.		-5.53%
Average		+34.71%
Weighted average by Cap.		+13.06%